Islet cell transplantation carries significant medical risks, primarily related to the lifelong requirement for potent immunosuppressive drugs to prevent graft rejection, which can increase susceptibility to severe infections and malignancies. Other procedure-specific risks include bleeding, blood clots in the portal vein, temporary or permanent fluctuations in blood glucose control, and the possibility of primary non-function where transplanted cells fail to produce sufficient insulin.